Zenas BioPharma, Inc.
No SEC Form 4 filings for $ZBIO in the last 30 days.
See all $ZBIO insider activity →Morgan Stanley initiated coverage on Zenas Biopharma (ZBIO) with an Equalweight rating and $32 price target, citing 20% upside. The firm highlights obexelimab's potential for IgG4-related disease, estimating $650M sales by 2035. Analysts generally rate ZBIO as Strong Buy with targets up to $59. The company has a solid balance sheet but may be overvalued, per InvestingPro.
HC Wainwright & Co. maintained a Buy rating on Zenas BioPharma (ZBH) with a $44 price target, suggesting a 66.7% upside. The firm cited positive data on obexelimab's efficacy and initial vaccine sub-study results.
Zenas Bio reported Phase 3 data for obexelimab, showing a 93% 12-month flare-free rate. The treatment reduced steroid toxicity and demonstrated vaccine response rates of 86% for influenza and 100% for COVID-19. Adverse event rates were low, supporting long-term safety, according to the company.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ZBIO (Zenas BioPharma, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ZBIO coverage spans financial news, technology and regulation.
Analyst initiation and a price target above current price suggest potential buying interest.
HC Wainwright & Co. maintained a Buy rating on Zenas BioPharma (ZBH) with a $44 price target, suggesting a 66.7% upside. The firm cited positive data on obexelimab's efficacy and initial vaccine sub-study results.
Positive Phase 3 data is likely to lift ZBIO as investors price in a potential label‑ready product.
Positive long‑term efficacy and safety data may boost investor confidence in ZBIO’s lead asset.
Upcoming data could drive short-term interest and potential upside if results are positive.
AlphAI scores every news story that mentions ZBIO with an AI model for sentiment and relevance, and aggregates insider trades from Zenas BioPharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Morgan Stanley initiated coverage on Zenas Biopharma (ZBIO) with an Equalweight rating and $32 price target, citing 20% upside. The firm highlights obexelimab's potential for IgG4-related disease, estimating $650M sales by 2035. Analysts generally rate ZBIO as Strong Buy with targets up to $59. The company has a solid balance sheet but may be overvalued, per InvestingPro.
2 min readHC Wainwright & Co. maintained a Buy rating on Zenas BioPharma (ZBH) with a $44 price target, suggesting a 66.7% upside. The firm cited positive data on obexelimab's efficacy and initial vaccine sub-study results.
1 min readZenas Bio reported Phase 3 data for obexelimab, showing a 93% 12-month flare-free rate. The treatment reduced steroid toxicity and demonstrated vaccine response rates of 86% for influenza and 100% for COVID-19. Adverse event rates were low, supporting long-term safety, according to the company.
1 min readZenas BioPharma, Inc. (ZBIO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease | Source: Zenas BioPharma Share – Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activit
2 min readZenas BioPharma (ZBIO) will present data on orelabrutinib and obexelimab at MSToronto2026, including Phase 2 and Phase 3 trial results for multiple sclerosis. The company will also host a symposium on BTK inhibition in MS. Orelabrutinib is in Phase 3 trials for PPMS and naSPMS, while obexelimab is in Phase 2 trials for RMS.
2 min readZenas BioPharma (ZBIO) reported Q2 results with a doubled net loss but FDA acceptance of its BLA for obexelimab in IgG4-related disease, with a target action date of May 27, 2027. The company also announced pipeline updates, including ongoing trials and international partnerships.
2 min readZenas BioPharma, Inc. (ZBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - - New study data confirm bioequivalence of obexelimab sing
6 min readZenas BioPharma (NASDAQ:ZBIO) reported positive Phase 3 INDIGO trial results for obexelimab in IgG4-related disease on June 2. The study met primary and key secondary endpoints, including a 56% reduction in flare risk vs placebo and lower glucocorticoid use. The company submitted a Biologics License Application to the FDA in May.
4 min readZenas BioPharma (Nasdaq: ZBIO) said it submitted a Biologics License Application to the U.S. FDA for obexelimab in IgG4-related disease, based on Phase 3 INDIGO results. The trial met the primary endpoint with a 56% reduction in flare risk vs placebo (HR 0.44, p=0.0005) and met four key secondary endpoints, with generally good tolerability.
4 min readZenas BioPharma (ZBIO) is progressing with its Phase 3 clinical trial for orelabrutinib, a BTK inhibitor, targeting primary progressive multiple sclerosis (PPMS). The study, which began recruitment in July 2025, aims to assess the drug's efficacy in slowing disability progression in a hard-to-treat patient population. The successful advancement of this trial could significantly enhance Zenas BioPharma's pipeline value, but investors are advised to monitor competitor developments as well.
3 min read
